NCT05888857View on ClinicalTrials.gov

MEDI5752 in Patients With Mature Tertiary Lymphoid Structures Solid Tumors.

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

102

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

March 31, 2026

Study Completion Date

September 30, 2028

Conditions

Advanced Solid Tumor

Interventions

DRUG

MEDI5752

A treatment cycle consists of 3 weeks. MEDI5752 will be administered by intravenous infusion at a fixed dose on Day 1 of each cycle

Trial Locations (1)

33076

Institut Bergonie, Bordeaux

Sponsors

Lead Sponsor

Institut Bergonié

Collaborators (1)

All Listed Sponsors

collaborator

National Cancer Institute, France

OTHER_GOV

collaborator

AstraZeneca

INDUSTRY

lead

Institut Bergonié

OTHER

NCT05888857 - MEDI5752 in Patients With Mature Tertiary Lymphoid Structures Solid Tumors. | Biotech Hunter | Biotech Hunter